Journal article
Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome
SD Goyal, M-J Zhang, H-L Wang, G Akpek, EA Copelan, C Freytes, RP Gale, M Hamadani, Y Inamoto, RT Kamble, HM Lazarus, DI Marks, T Nishihori, RF Olsson, R Reshef, DS Ritchie, W Saber, BN Savani, A Seber, TC Shea Show all
BONE MARROW TRANSPLANTATION | NATURE PUBLISHING GROUP | Published : 2015
DOI: 10.1038/bmt.2015.82
Abstract
The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant Research, we compared the outcomes of patients who had EMD of AML at any time before transplant, with a cohort of AML patients without EMD. We reviewed data from 9797 AML patients including 814 with EMD from 310 reporting centers and 44 different countries, who underwent alloHCT between and 1995 and 2010. The primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included leukemia-free survival (LFS), relapse rate and treatment-related mortality (TRM). In a multiva..
View full abstractGrants
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Awarded by NCI NIH HHS
Awarded by NHLBI NIH HHS
Awarded by PHS HHS